Neil Exter - 16 Jun 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Director
Issuer ticker: RVMD
Reported as of: 16 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2022, 17:12:19 UTC
Prior SEC filing: 10 Jun 2022
Next SEC filing: 21 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Neil Exter

Key filing fact

Neil Exter filed Form 4 for Revolution Medicines, Inc. (RVMD) on 17 Jun 2022.

Key facts

This page summarizes Neil Exter's Form 4 filing for Revolution Medicines, Inc. (RVMD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2022, 17:12.

Change

Previous filing in this sequence was filed on 10 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Award

Transaction value: $0
Shares: +5,200
Change %: +22%
Price: $0.000000
Shares after: 28,815
Date: 16 Jun 2022
Ownership: Direct
Footnotes: F4

RVMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 16 Jun 2022
Ownership: See footnotes
Footnotes: F1, F2

RVMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 19,998
Date: 16 Jun 2022
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +18,400
Change %
Price: $0.000000
Shares after: 18,400
Date: 16 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,400
Exercise price: $16.80
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Reporting Person is a partner of each of Third Rock Ventures GP II, L.P., Third Rock Ventures GP III, L.P. and Third Rock Ventures GP IV, L.P. which is the general partner of each of Third Rock Ventures II, L.P. ("TRV II), Third Rock Ventures III, L.P. ("TRV III") and Third Rock Ventures IV, L.P. ("TRV IV" and collectively with TRV II and TRV III, "the Funds"), respectively. The Reporting Person disclaims beneficial ownership over the shares held by the Funds, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

Footnote F2

TRV III directly holds 5,104,130 shares of Common Stock of the Issuer and TRV IV directly holds 1,419,900 shares of Common Stock of the Issuer.

Footnote F3

The shares are directly held in certain estate-planning trusts over which the Reporting Person may have voting and dispositive power. The Reporting Person disclaims beneficial ownership over the shares held by such trusts except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

Footnote F4

Includes 5,200 Restricted Stock Units.

Footnote F5

Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 16, 2022 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.